

Delcath Systems Inc. (DCTH)

SEPTEMBER 25-26, 2024



Management - Delcath Systems Inc.

Gerard Michel
CEO

Sandra Pennell
Senior Vice President of Finance

Space will be limited. Meeting times and itinerary subject to change. To join the meetings or to obtain more information, please contact your Stephens sales representative.

Roadshow Host

Sudan Loganathan, PhD
Research Analyst
Biotechnology
(212) 891-1762
sudan.loganathan@stephens.com

About Delcath Systems Inc.

Delcath Systems, Inc. (Nasdaq: DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT (Hepzato (Melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. DCTH is headquartered in Queensbury, NY.